HCPCS code Q0515
Injection, sermorelin acetate, 1 microgram
What Q0515 means
Q0515 (Sermorelin acetate injection) belongs to the HCPCS Level II Q series (Temporary Codes). Its Medicare coverage status is Special coverage instructions apply. Review the relevant Medicare manual or National Coverage Determination before billing.
Part B pricing: Drugs.
Code details
- Short description
- Sermorelin acetate injection
- Coverage code
- D = Special coverage instructions apply
- Pricing indicator
- 51 = Drugs
- Multiple pricing indicator
- A = Not applicable as HCPCS priced under one methodology
- Type of service
- 1 = Medical care P = Lump sum purchase of DME, prosthetics, orthotics
- Action code
- N = No maintenance for this code
- Action effective date
- January 01, 2006
- Code added date
- January 01, 2006
- Data year
- 2026
Questions about Q0515
What is HCPCS code Q0515?
HCPCS code Q0515 is a Level II code in the Q series (Temporary Codes). Its full description is: "Injection, sermorelin acetate, 1 microgram"
Is Q0515 a CPT code?
No. Q0515 is a HCPCS Level II code maintained by CMS, not a CPT (Level I) code from the American Medical Association. People often search for it as a CPT code because both code sets are reported on the same claims.
Does Medicare cover HCPCS code Q0515?
The Medicare coverage code for Q0515 is "Special coverage instructions apply". Review the relevant Medicare manual or National Coverage Determination before billing.
When was HCPCS code Q0515 added?
Q0515 was added to the HCPCS code set on January 01, 2006. The most recent action on it (No maintenance for this code) took effect on January 01, 2006.
Nearby Q codes
All Q codes- Q0510Pharmacy supply fee for initial immunosuppressive drug(s), first month following transplant
- Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period
- Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period
- Q0513Pharmacy dispensing fee for inhalation drug(s); per 30 days
- Q0514Pharmacy dispensing fee for inhalation drug(s); per 90 days
- Q0516Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 30-days
- Q0517Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 60-days
- Q0518Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 90-days
- Q0519Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 30-days
- Q0520Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 60-days